Malignant hypethermia in Japan - Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct Sequencing

被引:95
作者
Ibarra, Carlos A. [1 ]
Wu, Shiwen [1 ]
Murayama, Kumiko [1 ]
Minami, Narihiro [1 ]
Ichihara, Yasuko [1 ]
Kikuchi, Hirosato [1 ]
Noguchi, Satoru [1 ]
Hayashi, Yukiko K. [1 ]
Ochiai, Ryoichi [1 ]
Nishino, Ichizo [1 ]
机构
[1] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Tokyo 1878502, Japan
关键词
D O I
10.1097/00000542-200606000-00008
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Malignant hyperthermia (MH) is a disorder of calcium homeostasis in skeletal muscle triggered by volatile anesthetics or succinylchollne in susceptible persons. More than 100 mutations in the ryanodine receptor type 1 gene (RYR1) have been associated with MH susceptibility, central core disease, or both. RYR1 mutations may account for up to 70% of MH-susceptible cases. The authors aimed to determine the frequency and distribution of RYR1 mutations in the Japanese MH-susceptible population. Methods: The authors selected 58 unrelated Japanese diagnosed as MH-susceptible for having an enhanced Ca2+-induced Ca2+ release rate from the sarcoplasmic reticulum on chemically skinned muscle fibers. They sequenced the entire RYR1 coding region from genomic DNA. Muscle pathology was also characterized. Results: Seven previously reported and 26 unknown RYR1 potentially pathogenic sequence variations were identified in 33 patients (56.9%). Of these patients, 48% had cores on muscle biopsy. The mutation detection rate was higher in patients with clear enhancement of Ca2+-induced Ca2+ release rate (72.4%), whereas all patients with central core disease had RYR1 mutations. Six patients harbored potentially causative compound heterozygous sequence variations. Conclusions: Distribution and frequency of RYR1 mutations differed markedly from those of the North American and European MH-susceptible population. Comprehensive screening of the RYR1 gene is recommended for molecular investigations in MH-susceptible individuals, because many mutations are located outside the "hot spots." Based on the observed occurrence of compound heterozygous state, the prevalence of a possibly predisposing phenotype in the Japanese population might be as high as 1 in 2,000 people.
引用
收藏
页码:1146 / 1154
页数:9
相关论文
共 46 条
[1]   Screening of the ryanodine receptor gene in 105 malignant hyperthermia families:: novel mutations and concordance with the in vitro contracture test [J].
Brandt, A ;
Schleithoff, L ;
Jurkat-Rott, K ;
Klingler, W ;
Baur, C ;
Lehmann-Horn, F .
HUMAN MOLECULAR GENETICS, 1999, 8 (11) :2055-2062
[2]   Ryanodine receptor defects in muscle genetic diseases [J].
Brini, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 322 (04) :1245-1255
[3]   Malignant hyperthermia in infancy and identification of novel RYR1 mutation [J].
Chamley, D ;
Pollock, NA ;
Stowell, KM ;
Brown, RL .
BRITISH JOURNAL OF ANAESTHESIA, 2000, 84 (04) :500-504
[4]   Malignant hyperthermia [J].
Denborough, M .
LANCET, 1998, 352 (9134) :1131-1136
[5]  
DEUFEL T, 1995, AM J HUM GENET, V56, P1334
[6]   CHANGES IN THE CA-INDUCED CA RELEASE MECHANISM IN THE SARCOPLASMIC-RETICULUM OF THE MUSCLE FROM A PATIENT WITH MALIGNANT HYPERTHERMIA [J].
ENDO, M ;
YAGI, S ;
ISHIZUKA, T ;
HORIUTI, K ;
KOGA, Y ;
AMAHA, K .
BIOMEDICAL RESEARCH-TOKYO, 1983, 4 (01) :83-92
[7]   Ryanodine receptor calcium release channels [J].
Fill, M ;
Copello, JA .
PHYSIOLOGICAL REVIEWS, 2002, 82 (04) :893-922
[8]   Molecular genetic testing for malignant hyperthermia susceptibility [J].
Girard, T ;
Treves, S ;
Voronkov, E ;
Siegemund, M ;
Urwyler, A .
ANESTHESIOLOGY, 2004, 100 (05) :1076-1080
[9]   JS']JSNP: a database of common gene variations in the Japanese population [J].
Hirakawa, M ;
Tanaka, T ;
Hashimoto, Y ;
Kuroda, M ;
Takagi, T ;
Nakamura, Y .
NUCLEIC ACIDS RESEARCH, 2002, 30 (01) :158-162
[10]   Effect of bupivacaine enantiomers on Ca2+ release from sarcoplasmic reticulum in skeletal muscle [J].
Ibarra, CA ;
Ichihara, Y ;
Hikita, M ;
Yoshida, K ;
Junji, S ;
Maehara, Y ;
Kikuchi, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 512 (2-3) :77-83